Skip to main content
. 2022 Jan 24;28(1):104–116. doi: 10.1038/s41591-021-01615-z

Extended Data Fig. 9. The effect of ION363 on FUS expression and pathology in human motor cortex.

Extended Data Fig. 9

(a) Immunohistochemical staining of FFPE sections of motor cortex (BA4) from a non-ALS control (left), ALS-FUSP525L control patient (middle), and ION363-treated ALS-FUSP525L patient (right) with an antibody against total FUS (FUS-Bethyl[400–450]). Scale bar=200 µm at 4x and 20 µm at 40x. (b) Immunohistochemical staining of FFPE sections of motor cortex (BA4) from a non-ALS control (left), ALS-FUSP525L control patient (middle), and ION363-treated ALS-FUSP525L patient (right) with P525L-specific guinea pig antiserum. Scale bar=200 µm at 4x and 20 µm at 40x. (c) Immunohistochemical staining of FFPE sections of motor cortex (BA4) from a non-ALS control (left), ALS-FUSP525L control patient (middle), and ION363-treated ALS-FUSP525L patient (right) with P525L-specific mouse monoclonal antibody. Scale bar=200 µm at 4x and 20 µm at 40x.